

### **CLAIM AMENDMENTS**

Please amend claims 29 and 39-41 and please cancel claims 30-34, 36, and 38 without prejudice or disclaimer. The following listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Previously Presented) A pharmaceutical composition comprising an isolated heat shock protein (HSP) consisting of SEQ ID NO: 47 in an effective amount to promote fugetactic activity and a pharmaceutically acceptable carrier.

2. – 28. (Cancelled)

29. (Currently Amended) A method of promoting fugetaxis of migratory cells in a subject, comprising: administering to a subject in need of such treatment the Heat Shock Protein (HSP) of SEQ ID NO:3 or a fragment thereof consisting of SEQ ID NO: 47, in an amount effective to promote fugetaxis of migratory cells away from a specific site in a subject, wherein the specific site is a medical device, prosthetic device or a transplanted organ or tissue that is xenogeneic, stem-cell derived, synthetic or an allograft.

30-34. (Cancelled)

35. (Currently Amended) The method of claim ~~33~~29, wherein the medical device~~[[.]]~~ or ~~prosthetic device or a transplanted organ or tissue~~ is a stent.

36. (Cancelled)

37. (Currently Amended) ~~The method of claim 36, wherein~~A method of promoting fugetaxis of migratory cells in a subject, comprising: administering to a subject in need of such treatment the Heat Shock Protein (HSP) of SEQ ID NO:3 or a fragment thereof consisting of SEQ ID NO: 47, in an amount effective to promote fugetaxis of migratory cells away from a specific site in a subject, wherein the specific site is a~~the-site of an autoimmune reaction is a site-at or near a joint.~~

38. (Cancelled)

39. (Currently Amended) ~~The method of claim 29A~~ method of promoting fugetaxis of migratory cells in a subject, comprising: administering to a subject in need of such treatment the Heat Shock Protein (HSP) of SEQ ID NO:3 or a fragment thereof consisting of SEQ ID NO: 47, in an amount effective to promote fugetaxis of migratory cells away from a specific site in a subject, wherein the pharmaceutical composition is administered locally.
40. (Currently Amended) ~~The method of claim 29A~~ method of promoting fugetaxis of migratory cells in a subject, comprising: administering to a subject in need of such treatment the Heat Shock Protein (HSP) of SEQ ID NO:3 or a fragment thereof consisting of SEQ ID NO: 47, in an amount effective to promote fugetaxis of migratory cells away from a specific site in a subject, wherein the pharmaceutical composition is administered systemically.
41. (Currently Amended) ~~The method of claim 29A~~ method of promoting fugetaxis of migratory cells in a subject, comprising: administering to a subject in need of such treatment the Heat Shock Protein (HSP) of SEQ ID NO:3 or a fragment thereof consisting of SEQ ID NO: 47, in an amount effective to promote fugetaxis of migratory cells away from a specific site in a subject, wherein the HSP is conjugated to a targeting molecule.
42. (Original) The method of claim 29, wherein the migratory cells are hematopoietic cells.
43. (Currently Amended) The method of claim ~~42~~29, wherein the hematopoietic cells are immune cells.
44. (Currently Amended) The method of claim ~~43~~29, wherein the immune cells are T cells.
45. – 124. (Cancelled)